<DOC>
	<DOCNO>NCT02385123</DOCNO>
	<brief_summary>This open label single arm observational study longitudinal immunologic response influenza vaccine healthy adult subject . This study enroll male non-pregnant female , 18-49 year old . The subject screen enrollment history physical exam laboratory test ensure healthy enough participate . Qualifying subject vaccinated FDA approve seasonal inactivated influenza vaccine ( IIV ) accord package insert . The study enroll 10 healthy volunteer per vaccination season year 1 , 2 4 6 study , total enrollment 50 subject . The primary objective study characterize HA-specific plasmablast memory B cell influenza vaccination .</brief_summary>
	<brief_title>Evaluation Human Immune Responses Influenza Virus Vaccination Healthy Volunteers</brief_title>
	<detailed_description>This open label , single arm , observational study longitudinal immunologic response influenza vaccine healthy adult subject . This study enroll male non-pregnant female , 18-49 year old . The study duration 6 year participant duration 180 day . The subject screen enrollment history physical exam laboratory test ensure healthy enough participate . Qualifying subject vaccinated FDA approve seasonal inactivated influenza vaccine ( IIV ) accord package insert . Approximately 450 ml blood collect research assay course study . Specifically , 16 ml collect screening ; 48ml collect enrollment ; 96ml collect visit day 7 14 ; 64 ml collect 28 , 90 , 180 day post vaccination . The study enroll 10 healthy volunteer per vaccination season year 1 , 2 , 4 6 study , total enrollment 50 subject . Individuals complete study give option re-enroll subsequent year long continue meet inclusion/exclusion criterion . Re-enrolling subject re-consented , give new subject identifier , count towards enrollment number goal year participation . The primary objective study characterize HA-specific plasmablast memory B cell influenza vaccination secondary objective investigate longevity humoral immunity influenza virus human .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female subject 18 49 year age , inclusive 2 . Subjects capable provide write informed consent prior initiation study procedure . Subjects able understand comply plan study procedure available study visit 3 . Screening lab within normal limit per local laboratory normal range consider clinically significant investigator . Normal laboratory range list : A. Hematology : Hemoglobin : Male 12.916.1 gm/dL , Female 11.414.4 gm/dL White blood cell ( WBC ) : Male 4.29.2/uL , Female 410/uL Platelet count : 150400/uL B. Chemistries : Kidney function : Glomerular filtration rate ( GFR ) &gt; /= 60 mL/min/1.73 m^2 ; Liver enzymes : Albumin &gt; /= 3.5 g/dL ; ALT &lt; 66 U/L ; AST &lt; 62 U/L 4 . Subjects receive seasonal influenza vaccine current flu season suspect influenza infection current flu season . 5 . Female subject child bear potential must negative urine pregnancy test screen visit , enrollment visit subsequent study visit longer 14 day since last pregnancy test . 1 . Known infection HIV , HCV , HBV . This information obtain verbally patient . 2 . If female , active pregnancy breastfeed plan become pregnant study participation . 3 . Chronic medical condition cause immunodeficiency require medication could alter immune function immunosuppressant immunoenhancers . 4 . Have medical disease condition , opinion site principal investigator appropriate subinvestigator , contraindication study participation . This include chronic medical disease condition , define persist 3 month ( define 90 day ) long , would place subject unacceptable risk injury , render subject unable meet requirement protocol , may interfere evaluation response subject 's successful completion study 5 . Have acute illness , determine site principal investigator appropriate subinvestigator , within 72 hour prior study vaccination . An acute illness nearly resolve minor residual symptom remain allowable , opinion site principal investigator appropriate subinvestigator , residual symptom interfere ability ass safety parameter require protocol . 6 . Persons take anticoagulant , longterm aspirin therapy , longterm systemic steroid ( great 3 month past 12 month within 30 day ) . 7 . Have know hypersensitivity allergy egg , egg chicken protein component study vaccine ; 8 . Have know latex allergy ; 9 . Have history severe reaction follow previous immunization license influenza virus vaccine 10 . Have history GuillainBarre syndrome 11.Subjects suspected influenza infection current influenza season 12 . Subjects , screen , abnormal vital sign and/or physical exam , include temperature &gt; = 38.0 C , Systolic blood pressure &lt; =90 &gt; =160 mmHg , pulse &lt; = 60 &gt; 110 beat per minute , new rash , sign infection . 13 . Subjects already receive seasonal influenza vaccine current influenza vaccination season .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 7, 2016</verification_date>
	<keyword>ex-vivo</keyword>
	<keyword>Influenza</keyword>
	<keyword>plasmablast</keyword>
</DOC>